Fig. 5: Loss of heterozygosity in HLA (HLA LOH) in IPNs of different histologic stages and its association with chromosomal alterations. | Nature Communications

Fig. 5: Loss of heterozygosity in HLA (HLA LOH) in IPNs of different histologic stages and its association with chromosomal alterations.

From: Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

Fig. 5

a The proportion of AAH, AIS, MIA, and ADC lesions with evidence of HLA-LOH. Two-sided χ2 test was used to assess the difference among different histologic stages. Comparison of AI burden (number of AI events) (b) and CNV burden (normalized as the percent of genes with CNV) (c) in lesions with (purple) and without (green) HLA-LOH. Two-sided Wilcoxon rank-sum test was used to assess the differences. Error bars indicate 95% confidence intervals and solid point represent mean value in each stage. Data from 35 patients was used including NL (normal lung tissue), AAH (atypical adenomatous hyperplasia), AIS (adenocarcinoma in situ), MIA (minimally invasive adenocarcinoma), ADC (invasive adenocarcinoma). (Source data is provided as a source data file).

Back to article page